{"id":"W4316506412","doi":"10.1093/cid/ciad023","title":"Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institutes of Health; University of Cape Town; National Research Foundation; National Institute of Allergy and Infectious Diseases; McMaster University; Wellcome Trust; Wellcome","keywords":"Dolutegravir; Medicine; Emtricitabine; Efavirenz; Lamivudine; Placebo; Dosing; Randomized controlled trial; Adverse effect; Internal medicine; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003234347,0.002170072,0.005505735,0.0008450659,0.000653738,0.001725525,0.001471316,0.00343831,0.01248058],"category_scores_gemma":[0.003352609,0.001071253,0.002504727,0.0007599907,0.001764314,0.00167035,0.0005913506,0.003111463,0.001503857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009141789,"about_ca_system_score_gemma":0.001517825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007887535,"about_ca_topic_score_gemma":0.001568679,"domain_scores_codex":[0.9983981,0.0008241247,0.0001436495,0.0003209079,0.0001329581,0.0001802111],"domain_scores_gemma":[0.998281,0.0005820997,0.0003957098,0.00016073,0.0001617592,0.0004187176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9892746,0.003914733,0.00008987795,0.0007644331,0.0004501677,0.00001781483,0.00002857992,0.00007046069,0.0009058284,0.0000480524,0.0002014495,0.004234031],"study_design_scores_gemma":[0.9833221,0.01611094,0.0001453217,0.00002000985,0.0001159389,0.000005376064,0.000005508826,0.00006484707,0.00006007568,0.00002921649,0.0001168633,0.00000383185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9496795,0.01471792,0.0020619,0.001319368,0.002845945,0.02335829,0.002080329,0.000393536,0.003543216],"genre_scores_gemma":[0.960731,0.006785084,0.00319632,0.001856891,0.001352005,0.02058384,0.001050794,0.00003932129,0.004404753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01248058,"threshold_uncertainty_score":0.04175174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08331070069054886,"score_gpt":0.4208768176560899,"score_spread":0.3375661169655411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}